exRNAdisease

Entry Detail

---



General Information

Database ID: exR0274357 RNA Name: hsa-let-7d-5p RNA Type: miRNA Chromosome: chr9 Starnd: + Coordinate: Start Site(bp): 94178841 End Site(bp): 94178862 External Links: hsa-let-7d-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE22981 Description: Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: Early satge breast cancer Case Sample: Breast Cancer Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand TECPR2 chr14 102362941 102502477 + DDB2 chr11 47214465 47239240 + RPL41 chr12 56116590 56117967 + ZCCHC9 chr5 81301587 81313297 + BCAM chr19 44809071 44821421 + BACH1 chr21 29194071 29630751 + HMGA2 chr12 65824131 65966295 + PLPP6 chr9 4662294 4665258 + CSNK1E chr22 38290691 38318084 - ACTG1 chr17 81509971 81523847 - CTPS2 chrX 16587999 16712936 - YOD1 chr1 207043849 207052980 - SH3PXD2B chr5 172325000 172454525 - BLOC1S6 chr15 45587214 45615945 + C15orf41 chr15 36579626 36810248 + GRPEL2 chr5 149345430 149354583 + ACP1 chr2 264140 278283 + IGF2BP1 chr17 48997385 49056145 + MNT chr17 2384073 2401104 - PPARA chr22 46150521 46243756 + PRMT1 chr19 49675786 49689029 + IGDCC3 chr15 65327127 65378002 - ARID3B chr15 74541177 74598131 + TRIM65 chr17 75880335 75896951 - HMGCS1 chr5 43287470 43313512 - VPS26C chr21 37223420 37267919 - DHX15 chr4 24517441 24584554 - HMGA1 chr6 34236873 34246231 + HDLBP chr2 241227264 241317061 - UBE2G2 chr21 44768580 44801826 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000247 chr10 74474868 74475660 + hsa_circ_0000987 chr2 30748452 30756180 + hsa_circ_0000246 chr10 74468040 74475660 + hsa_circ_0000018 chr1 15860731 15863309 + hsa_circ_0000038 chr1 28800065 28802803 + hsa_circ_0000799 chr17 65941524 65972074 + hsa_circ_0001164 chr20 45891031 45923523 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC006064.5 chr12 6510275 6510522 + AC074117.1 chr2 27356246 27367622 + AC109460.3 chr16 28974804 28990775 + AC124045.1 chr3 44667412 44669364 + AP000766.1 chr11 107312132 107316271 - ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - KCNQ1OT1 chr11 2608328 2699994 - LINC00265 chr7 39733430 39793092 + LINC02381 chr12 54126082 54147485 + MIRLET7BHG chr22 46053869 46113928 + NEAT1 chr11 65422774 65445540 + NUTM2A-AS1 chr10 87201647 87342612 - SNHG16 chr17 76557764 76565348 + SNHG4 chr5 139274102 139284899 + TMPO-AS1 chr12 98512973 98516422 - XIST chrX 73820649 73852723 - ZNF436-AS1 chr1 23368997 23371839 + LINC01001 chr11 127204 139612 - Display:

Experiment Detail

GEO ID: GSE22981 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 801 Sample treatment protocol: NA RNA Extract protocol: Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications. RNA library preparation protocol: Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).

Reference

PMID: 21060830 Title: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer Author: Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer. Journal: PLoS One. 2010 Oct 29;5(10):e13735. Description: The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.